Injectable drug delivery is considered one of the most effective routes of administration due to the speed and effectiveness of delivery to the target, as well as the improved patient experience. The global injectable drug delivery market continues to grow and technology is advancing. This, coupled with the ever-changing regulatory requirements, means that it is imperative for companies to stay abreast of the latest developments and challenges within the industry in order to remain compliant, as well as gaining a competitive edge.
This seminar has been designed for all those working in the industry to discover the next generation of injectable drugs and devices and get an update on the latest trends, technologies and applications. Attending this event will provide a great opportunity to network with industry leaders, as well as like-minded professionals, to share common experience and best practice.
Attending this two-day seminar, presented by key industry experts, will:
This meeting runs back-to-back with Pre-filled Syringes and there is a further £200/€280 discount when booked together with this programme.
To find out more call Customer Services on +44 (0)20 7749 4730 or e-mail email@example.com
Previous Exhibitors Include:
Exhibition opportunities are available. Please contact Customer Services on +44 (0)20 7749 4730
or contact us through our contact form.
This conference will be of particular interest to:
Scientists and management in medical devices, pharmaceutical and biotechnology companies working in parenteral delivery. Personnel responsible for device programmes, product development, regulatory affairs and product lifecycle management will find this event beneficial. Previous delegates include: Directors, Senior Executives in R&D, Head of Device Departments, Combination Products Specialists, Drug Delivery Managers, Business Development Executives, Product Development Managers and those in Project Co-ordination and Marketing roles.
Chair’s welcome and introduction
Dr Gregory Berman
The evolving market for self-injection devices, differentiation through patient-friendly drug delivery devices
Assessing injection site pain
Challenges with high-volume and high-viscous drug formulations
Approaches to combination product control
Pre-filled syringes over time
Using polymeric PDC technology to improve auto-injector design
Connected needle-free drug delivery: innovative technology to differentiate your brand
Interactive panel discussion: opportunities for connectivity with hand-held injection devices
Moderator: Dr Gregory Berman
Panellists: Dr Thomas Schönknecht, Chris Muenzer and Barb Taylor
Networking drinks reception
Review of day one Dr Gregory Berman
Demand for large volume injectors for 2-10 ml injection volumes
Challenges of medical delivery in acute and chronic care settings – implications for delivery design
From the treatment chair to the sofa – innovative concept for wearable injection
Update on the Ominpod device
The EU regulatory framework for injectable delivery systems
Planned changes to the 11608 series of ISO standards and their implications on device design
Interactive panel discussion: opportunities with wearable and large volume injectors
Moderator: Dr Gregory Berman
Panellists: Ian Thompson and Stephen Augustyn
Chair’s closing remarks
End of seminar and refreshments
Dr. Andreas Rothmund is Qualified Person at Vetter Pharma-Fertigung in Ravensburg, Germany, an independent contract manufacturer specialised in the aseptic production of pre-filled application systems. He started his industrial career in 1985 as a lab manager. After two years he took over production responsibility for a German company specialised in eye drops and eye ointments, a position he held for nearly eight years.
He joined Vetter in 1994, where he has held several positions, including Head of Production for one of Vetter’s aseptic production units. He holds a degree in organic chemistry from the University of Constance, Germany.
Gregory Berman is an Independent Consultant and Director of Cantab Innovations Ltd. Previously he was Head of the Medical Group at Kinneir Dufort, an award-winning research, innovation, design and product development company, with over 30 years’ experience helping companies discover, create, develop and realise tangible new products, brands and experiences. He helps clients in the life-science, medical and healthcare sectors to develop products in complex situations, optimise life-science R&D and exploit technology strategically.
He led the design and development of SmartJect™; an autoinjector which automatically retracts the needle and was launched by J&J in 2010 with an important next-generation drug.
Worked with Chrono Therapeutics, helping to develop their SmartStop™ based device, the world’s first programmable, wearable transdermal smoking cessation therapy.
Participated in a detailed design review of an autoinjector being developed by a leading pharmaceutical company for a new drug.
Undertook the Voice of Customer study for a leading biopharmaceutical company, as the starting point for developing high volume parenteral delivery devices for lifesaving immunotherapies.
Undertook a technology survey for a company interested in needle-free, transdermal, micro-needle, electroporation and iontophoresis drug delivery devices.
Ian Thompson has been Vice President Business Development, Delivery Systems with Ypsomed AG since 1995. He has had a number of roles in key account management and business development working with pharma companies to develop and bring to market innovative self-injection systems. He studied biochemistry and biotechnology in the UK from 1979-1983 and has worked in medical device companies since moving to Switzerland in 1990. Following the successful development and launch of a range of new pen and autoinjector custom products, Ypsomed Delivery Systems’ continues to focus on the development of next generation pen, autoinjector and bolus injector technologies.
Dr. Patrick Anquetil is Portal Instrument’s Chief Executive Officer. He brings more than 18 years of experience in nanotechnology, including extensive knowledge in the areas of cleantech, material science, and instrumentation.
From 2009 to 2012, he was co-founder and director of strategic and process planning for SynapDx Corporation, where he had responsibility for development of the company’s business and operational plans as well as securing $9 million in Series A funding. He began his career as a science and nanotechnology equity research analyst at Susquehanna International Group, authoring and marketing nanotechnology industry and equity research reports to hedge funds and portfolio managers. He holds a doctorate in bio-instrumentation from MIT, an MBA from Harvard University, and a master’s degree from the ETH in Zurich and the University of Tokyo. His work has appeared in numerous peer-reviewed publications as well as mainstream media, including MIT Technology Review, Wired Magazine, PBS, and CNBC among others.
Neil is the Head of Connected Health and Director of Front-End Innovation for Phillips-Medisize, based in Cambridge UK. Neil consults for BioPharma clients, innovating and executing strategies to enhance stakeholder engagement through connected devices and service design. He has over 22 years’ commercial experience covering medical devices, telemetry, digital imaging, clinical decision support, secure mobile working, patient engagement and health analytics for businesses including Philips Healthcare, Microsoft, Elsevier Health Sciences, Hospira, Map of Medicine and ZOLL. Prior to Neil’s commercial career he trained at Leicester University Hospitals in Operating Department Practice and was Faculty for numerous Advanced Life Support programs having qualified in the UK and United States.
Chris Muenzer is a Senior Device Technology Manager at Novartis in Basel, Switzerland. He has almost 20 years of development experience with a focus on drug delivery devices and has filed several patents in the field. At Novartis, Mr. Muenzer leads a team supporting injectable delivery systems for Novartis’ diverse portfolio of drugs. In addition to his work at Novartis, he is active on the ISO working group for injection devices. Mr. Muenzer holds a BSME from Carnegie Mellon University in Pittsburgh, Pennsylvania in the US.